Skip to main navigation
Skip to search
Skip to main content
Tel Aviv University Home
Update Request & User Guide (TAU staff only)
Home
Experts
Research units
Research output
Datasets
Prizes
Activities
Press/Media
Search by expertise, name or affiliation
Tetrabenazine in the treatment of Huntington's disease
Diana Paleacu
*
*
Corresponding author for this work
Neurology
Abarbanel Mental Health Center
Research output
:
Contribution to journal
›
Review article
›
peer-review
67
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Tetrabenazine in the treatment of Huntington's disease'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Huntington's Disease
100%
Tetrabenazine
100%
Chorea
50%
Clinical Efficacy
50%
Schizophrenia Treatment
25%
Dopamine
25%
Mechanism of Action
25%
Tardive Dyskinesia
25%
Abnormal Involuntary Movements
25%
Catecholamines
25%
Neurological Diseases
25%
Reserpine
25%
Tolerability
25%
Myoclonus
25%
Pharmacokinetics
25%
Dyskinesia
25%
Primary Dystonia
25%
Dystonia
25%
Tourette Syndrome
25%
Stud
25%
Hyperkinetic Movement Disorders
25%
Pharmacology, Toxicology and Pharmaceutical Science
Huntington Chorea
100%
Tetrabenazine
100%
Dyskinesia
50%
Chorea
50%
Dystonic Disorder
50%
Side Effect
25%
Tardive Dyskinesia
25%
Myoclonus
25%
Motor Dysfunction
25%
Neurologic Disease
25%
Catecholamine
25%
Reserpine
25%
Tolerability
25%
Gilles De La Tourette Syndrome
25%
Tic
25%
Pharmacokinetics
25%